PDSB Stock Price, PDS Biotechnology Corp Quote, Chart

Market Summary

USD3.49-0.04

Market Closed

-1.13%

PDSB Stock Price

View Fullscreen

PDSB RSI Chart

PDSB Valuation

Market Cap

128.0M

Price/Earnings (Trailing)

-2.92

Price/Sales (Trailing)

147.24

EV/EBITDA

-1.24

Price/Free Cashflow

-4.21

PDSB Price/Sales (Trailing)

PDSB Profitability

EBT Margin

-6173.56%

Return on Equity

-118.03%

Return on Assets

-63.6%

Free Cashflow Yield

-23.74%

PDSB Fundamentals

PDSB Revenue

Revenue (TTM)

871.9K

PDSB Earnings

Earnings (TTM)

-43.9M

Earnings Growth (Yr)

-9.77%

Earnings Growth (Qtr)

2.7%

Breaking Down PDSB Revenue

Last 7 days

-0.6%

Last 30 days

28.3%

Last 90 days

-35.4%

Trailing 12 Months

-52.8%

How does PDSB drawdown profile look like?

PDSB Financial Health

Current Ratio

4.56

PDSB Investor Care

Shares Dilution (1Y)

19.00%

Diluted EPS (TTM)

-1.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2018	851.3K	944.4K	917.6K	871.9K
2017	265.7K	385.3K	543.3K	700.9K
2016	51.8K	99.8K	154.5K	212.3K
2015	0	5.0K	7.0K	9.1K
2014	0	0	3.4K	2.9K
2013	0	0	0	4.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of PDS Biotechnology Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 02, 2022	bedu-addo frank	acquired	1,442,340	6.57	219,535	president/ceo
Dec 02, 2022	bedu-addo frank	sold (taxes)	-1,713,300	9.78	-175,184	president/ceo
Dec 13, 2021	hill matthew c	bought	900	9.00	100	chief financial officer
Dec 13, 2021	hill matthew c	bought	26,060	8.98621	2,900	chief financial officer
Jun 16, 2021	bloomquist delyle w	bought	98,778	9.8778	10,000	-
Jun 16, 2021	bloomquist delyle w	acquired	17,790	5.99	2,970	-
Jun 15, 2021	van voorhees seth	bought	150,000	8.5	17,647	chief financial officer
Jun 15, 2021	glover steve c	bought	49,997	8.5	5,882	-
Jun 15, 2021	freitag gregory gene	bought	49,997	8.5	5,882	-

Which funds bought or sold PDSB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	269	196,905	298,104	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.16	-11,602	11,270	-%
May 15, 2024	Corton Capital Inc.	sold off	-100	-75,296	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-73.23	-44,000	12,000	-%
May 15, 2024	Voya Investment Management LLC	sold off	-100	-59,824	-	-%
May 15, 2024	Iron Gate Global Advisors LLC	unchanged	-	-77,995	294,835	0.05%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	sold off	-100	-1,988,000	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-63,203	-	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	163,235	163,235	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-201,663	-	-%

Are Funds Buying or Selling PDSB?

Are funds buying PDSB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PDSB

No. of Funds

Unveiling PDS Biotechnology Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 08, 2024	blackrock inc.	4.96%	1,821,621	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	1,881,438	SC 13G
Aug 27, 2021	hirschman orin	3.99%	1,135,398	SC 13G/A
Jun 21, 2021	hirschman orin	6.17%	1,750,000	SC 13G
Jun 21, 2021	netscientific plc	4.73%	1,342,670	SC 13D/A
Aug 21, 2020	netscientific plc	5.76%	1,282,670	SC 13D/A
Mar 02, 2020	netscientific plc	7.21%	1,046,670	SC 13D
Feb 21, 2020	peierls e jeffrey	6.95%	1,008,362	SC 13G

Recent SEC filings of PDS Biotechnology Corp

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report
May 08, 2024	SC 13G/A	Major Ownership Report
May 08, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 02, 2024	3	Insider Trading
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A

Peers (Alternatives to PDS Biotechnology Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

PDS Biotechnology Corp News

Latest updates

PDS Biotechnology Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2014Q4	2014Q3	2013Q4
Revenue	-6.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Operating Expenses	129.8%	2.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	159.1%	1.00	1.00	0.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	37.5%	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-5.5%	890*	942*	804*	959*	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-155.8%	-1.82	-0.71	-0.57	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	16.2%	69.00	59.00	57.00	64.00	68.00	77.00	75.00	56.00	61.00	67.00	72.00	77.00	28.00	31.00	34.00	20.00	24.00	14.00	19.00	26.00	31.00
Current Assets	16.3%	69.00	59.00	57.00	63.00	68.00	76.00	74.00	56.00	61.00	67.00	71.00	77.00	27.00	30.00	34.00	19.00	24.00	14.00	18.00	23.00	28.00
Cash Equivalents	17.8%	67.00	57.00	54.00	61.00	65.00	74.00	72.00	53.00	59.00	65.00	70.00	75.00	25.00	29.00	33.00	17.00	21.00	12.00	17.00	22.00	27.00
Net PPE	-3.5%	0.00	0.00	0.00	0.00	0.00	-	-	-	-	86*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-4.3%	32.00	33.00	33.00	31.00	27.00	33.00	28.00	5.00	5.00	4.00	4.00	4.00	3.00	4.00	-	-	4.00	3.00	-	-	-
Current Liabilities	10.5%	15.00	14.00	9.00	8.00	4.00	10.00	5.00	5.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	4.00	3.00	4.00	4.00	6.00
Shareholder's Equity	42.3%	37.00	26.00	24.00	32.00	41.00	44.00	47.00	51.00	56.00	63.00	68.00	73.00	24.00	27.00	31.00	17.00	20.00	12.00	16.00	21.00	24.00
Retained Earnings	-7.3%	-155	-144	-133	-122	-111	-101	-82.42	-75.00	-69.18	-60.70	-54.38	-47.42	-46.83	-43.79	-39.76	-35.85	-32.92	-28.94	-23.83	-18.08	-14.20
Additional Paid-In Capital	12.7%	192	171	158	155	152	146	129	126	125	124	122	120	71.00	71.00	71.00	53.00	53.00	41.00	39.00	39.00	39.00
Shares Outstanding	10.8%	37.00	33.00	31.00	31.00	31.00	30.00	28.00	28.00	26.00	28.00	25.00	23.00	22.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	148	-	-	-	98.00	-	-	-	340	-	-	-	23.00	-	-	-	18.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-17.5%	-9,938	-8,457	-7,175	-4,814	-13,188	-7,528	-5,892	-5,918	-6,369	-4,501	-5,128	946	-3,802	-4,629	-1,252	-4,103	-3,164	-5,519	-4,327	-4,858	-3,367
Share Based Compensation	20.3%	1,630	1,355	2,074	2,106	2,080	1,374	1,344	1,349	1,129	1,673	1,702	442	258	131	130	46.00	125	245	120	19.00	2,755
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	275	-	-	29,107
Cashflow From Financing	85.9%	20,012	10,766	802	240	4,568	9,707	24,551	22.00	7.00	13*	124	48,766	-	-	17,787	-	12,040	-	-	-	750

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PDSB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development expenses	$ 6,704,164	$ 5,843,686
General and administrative expenses	3,393,463	3,578,728
Total operating expenses	10,097,627	9,422,414
Loss from operations	(10,097,627)	(9,422,414)
Interest income (expenses), net
Interest income	668,895	729,341
Interest expense	(1,174,745)	(966,845)
Interest income (expense), net	(505,850)	(237,504)
Net loss	(10,603,477)	(9,659,918)
Comprehensive loss	$ (10,603,477)	$ (9,659,918)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.3)	$ (0.32)
Net loss per share, diluted (in dollars per share)	$ (0.3)	$ (0.32)
Weighted average common shares outstanding, basic (in shares)	34,815,870	30,428,053
Weighted average common shares outstanding, diluted (in shares)	34,815,870	30,428,053

PDSB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 66,634,417	$ 56,560,517
Prepaid expenses and other assets	2,051,348	2,494,558
Total current assets	68,685,765	59,055,075
Property and equipment, net	129,398	134,132
Financing lease right-to-use assets	191,203	200,873
Total assets	69,006,366	59,390,080
Current liabilities:
Accounts payable	6,000,831	6,982,824
Accrued expenses	1,714,111	2,424,692
Note payable - short term	7,291,667	4,166,667
Financing lease obligation-short term	57,081	55,794
Total current liabilities	15,063,690	13,629,977
Noncurrent liabilities:
Notes payable, net of debt discount	16,651,420	19,506,183
Financing lease obligation-long term	108,211	122,973
Total liabilities	31,823,321	33,259,133
STOCKHOLDERS' EQUITY
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2024 and December 31, 2023, 36,679,275 shares and 33,094,521 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	12,104	10,921
Additional paid-in capital	192,275,033	170,620,641
Accumulated deficit	(155,104,092)	(144,500,615)
Total stockholders' equity	37,183,045	26,130,947
Total liabilities and stockholders' equity	$ 69,006,366	$ 59,390,080

About PDS Biotechnology Corp

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

CEO	Dr. Frank K. Bedu-Addo Ph.D.
WEBSITE	pdsbiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	26

PDS Biotechnology Corp Frequently Asked Questions

What is the ticker symbol for PDS Biotechnology Corp? What does PDSB stand for in stocks?

PDSB is the stock ticker symbol of PDS Biotechnology Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PDS Biotechnology Corp (PDSB)?

As of Fri May 17 2024, market cap of PDS Biotechnology Corp is 128.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PDSB stock?

You can check PDSB's fair value in chart for subscribers.

What is the fair value of PDSB stock?

You can check PDSB's fair value in chart for subscribers. The fair value of PDS Biotechnology Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PDS Biotechnology Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PDSB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PDS Biotechnology Corp a good stock to buy?

The fair value guage provides a quick view whether PDSB is over valued or under valued. Whether PDS Biotechnology Corp is cheap or expensive depends on the assumptions which impact PDS Biotechnology Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PDSB.

What is PDS Biotechnology Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PDSB's PE ratio (Price to Earnings) is -2.92 and Price to Sales (PS) ratio is 147.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PDSB PE ratio will change depending on the future growth rate expectations of investors.